Despite remarkable advances in HIV prevention strategies over the last 2 decades, 1.3 million people were diagnosed with new infections in 2022. Diversifying HIV prevention options is imperative because different populations may have different priorities that influence the acceptability, uptake, and durable use of prevention modalities. Realizing the potential of HIV prevention options requires understanding product tolerability across diverse groups vulnerable to HIV acquisition. Gender minority (GM) individuals are understudied in clinical trials.
Myron Cohen, MD, authored a report that looked at associations between gender and solicited adversed events after monoclonal antibody infusion. Gender minority participants reported more events; severity was low. HIV prevention trials must engage and support GM individuals to best evaluate tolerability of novel agents.